Shares of Kairos Pharma, Ltd. (KAPA) are currently trading 88.2937 percent higher after announcing positive interim safety results from its ongoing Phase 2 trial of ENV-105 or Carotuximab in patients with metastatic castration-resistant prostate cancer known as mCRPC.
The shares are currently at 1.2900, up 0.6049 points on a volume of 163,688,078 shares.
The company plans to engage with regulatory agencies to discuss the design of a potential pivotal Phase 3 trial, based on the positive emerging data from its ongoing study.
The company said trial of the CD105 antagonist in ten enrolled patients was well tolerated when combined with standard of care hormone therapy, apalutamide. No dose-limiting toxicities or unexpected adverse events reported to date.
The randomized Phase 2 trial aims to enroll 100 patients in total. Interim efficacy data from the trial are expected to be reported in September 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.